A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
Abstract Background FOLFIRINOX is a pillar first-line regimen in the treatment of pancreatic cancer. Historically, biliary tract cancer (BTC) and pancreatic cancer have been treated similarly with gemcitabine alone or combined with a platinum compound. With growing evidence supporting the role of fl...
Main Authors: | Ayhan Ulusakarya, Abdoulaye Karaboué, Oriana Ciacio, Gabriella Pittau, Mazen Haydar, Pamela Biondani, Yusuf Gumus, Amale Chebib, Wathek Almohamad, Pasquale F. Innominato |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-07004-y |
Similar Items
-
Inappropriateness in biliary stenting
by: Giuseppe Chesi, et al.
Published: (2013-10-01) -
FOLFIRINOX for advanced pancreatic adenocarcinoma in Brazil: a single-institution experience
by: José Mauricio Mota, et al.
Published: (2018-01-01) -
Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
by: Konstantin Schlick, et al.
Published: (2021-02-01) -
Role of MRCP in Differentiation of Benign and Malignant Causes of Biliary Obstruction
by: Meena Suthar, et al.
Published: (2015-11-01) -
Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient
by: Anne Katrin Berger, et al.
Published: (2017-12-01)